GOGL – 2025 AGM Results Notification Golden Ocean Group Limited (the “Company”) advises that the 2025 Annual General Meeting of the Shareholders of the Company was held on 8 May 2025 at 08:30 hrs, at Hamilton Princess and Beach Club, 76 Pitts Bay Road, Hamilton HMCX, Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2024 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight.To resolve that vacancies in the number of Directors be designated as c...
A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Coloplast A/S - Selskabsmeddelelse nr. 04/2025 - Regnskabsmeddelelse, 1. halvår 2024/25 Delårsrapport, første halvår 2024/25 1. oktober 2024 – 31. marts 2025 Coloplast leverede 6% organisk vækst i 2. kvartal, påvirket af produkttilbagekaldelsen i Urologi og et svagt kvartal i Stomi. Overskudsgraden1 i 2. kvartal holdt sig stabil på 27%. Den rapporterede omsætning målt i danske kroner steg 5%, påvirket af frasalget af hudplejeforretningen. Den organiske vækst pr. forretningsområde var 4% i Stomi, 8% i Kontinens, 7% i Stemme og Respiratorisk Pleje, 10% i Avanceret Sårpleje og -1% i Urol...
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25 Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostomy Care. Q2 EBIT margin1 held steady at 27%. Reported revenue in DKK grew 5%, impacted by the Skin Care divestment. Organic growth rates by business area: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10% and Interventional Urology -1%.Growth in Chronic Care was driven ...
Coloplast A/S CEO Kristian Villumsen steps down as of today Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy period, the Board of Directors has decided to initiate the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. As a result, President and CEO, Kristian Villumsen, steps down as of today. To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as...
Share buy-back program COMPANY ANNOUNCEMENT NO 25/2025 - May 5, 2025 On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016. The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The tot...
Coloplast A/S Revised guidance for FY 2024/25 Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic growth is now expected to be around 7%, from previously 8-9%. The EBIT margin before special items is now expected to be 27-28%, from previously around 28%. Key financial figures and developments in Q2: Group organic growth was 6% in Q2. The EBIT margin before special items was 27%.Organic growth rates by business area: Ostomy ...
Royal Unibrew’s Q1 was affected by a less-favourable Easter effect in the important Northern Europe region. While this was expected to some degree, the c4% top-line and c10% EBIT misses to consensus were a negative surprise. We reiterate our BUY, but have lowered our target price to DKK670 (690).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.